Loading...
Satellos Bioscience Inc.
MSCL.TO•TSX
HealthcareBiotechnology
CA$0.65
CA$0.01(1.54%)
Satellos Bioscience Inc. (MSCL.TO) Stock Overview
Explore Satellos Bioscience Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for MSCL.TOStats details for MSCL.TO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for MSCL.TOAnalyst Recommendations details for MSCL.TO are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
CEO
Mr. Francis Gleeson B.B.A. M.B.A
Employees
14
Headquarters
Royal Bank Plaza, Toronto, ON
Founded
2008